Markets

5 Sell-Ranked Biotechs That Fell More Than 5% Today

An image of a pen on an open laptop
Credit: Shutterstock photo

Despite being one of the most successful sectors in the past few years where the markets produced substantial returns, the Biotech sector has been struggling as of late. Most investors probably have seen this industry in the news quite a bit, but they may not realize the effects of this industry's decline. The biotech industry has strong ties to the healthcare sector, one that many investors are tied to in one way or another in their portfolios.

Friday was an especially tough day for many biotech stocks, and below are 5 that suffered losses of at least 5% on the day.

Acadia Pharmaceuticals(ACAD)

Focuses on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders is Acadia Pharmaceuticals. On Friday, the stock saw a decrease of -7.60%, closing the day at $34.15 per share. ACAD is currently a Zacks Rank #4 (Sell).

ANI Pharmaceuticals(ANIP)

ANI Pharmaceuticals engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company is currently a Zacks Rank #5 (Strong Sell) and on Friday suffered a decline of -6.47% as of market close.

Bluebird Bio Inc.(BLUE)

Bluebird Bio Inc is a biotech focused on the development, manufacture, and marketing of therapies for severe disorders. The company suffered a decline of -9.69% on Friday, and currently holds a Zacks Rank #4 (Sell).

Orexigen Therapeutics Inc.(OREX)

Orexigen Therapeutics Inc is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The company currently holds a Zacks Rank #4 (Sell). OREX had dropped -7.14% as of market close.

Alder Biopharmaceuticals(ALDR)

Alder Biopharmaceuticals currently holds a Zacks Rank #4 (Sell) and is a clinical-stage biopharmaceutical company that discovers, develops, and seeks to commercialize therapeutic antibodies. As of market close on Friday, the stock was down a substantial -9.25% to $33.86 a share.

Bottom Line

The biotech has had a rough time in the recent times, and at the moment it doesn't seem as though the end of this decline is in sight. It will be something to watch as this industry attempts to turn things around and finish out 2015 on a high note. Stay tuned to Zacks as we cover this industry as well as the popular healthcare industry that biotech's have strong ties to.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ACADIA PHARMA (ACAD): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

BLUEBIRD BIO (BLUE): Free Stock Analysis Report

OREXIGEN THERAP (OREX): Free Stock Analysis Report

ALDER BIOPHARMA (ALDR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ACAD ANIP BLUE

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More